About
Treatment for Enhancing Remyelination in Neurodegenerative Disorders
Glixogen Therapeutics is a biopharmaceutical company developing a treatment to enhance remyelination in neurodegenerative disorders that are driven by damage to the neuron's myelin sheath, such as multiple sclerosis (MS). Glixogen Therapeutics has discovered selective small molecule inhibitors of the transcription factor Gli1, a novel target that facilitates neuronal remyelination towards modifying the outcome of the disease. Glixogen Therapeutics was founded at the FutuRx biotechnology incubator.
Identity
| Name | Glixogen Therapeutics |
|---|---|
| Slug | glixogen-therapeutics |
| Type / kind | startup |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAoL3etN4IDA |
Status
| Status | inactive |
|---|---|
| Status reason | Non Active, Dec 2024 ceased to operate |
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ city | |
| HQ address | Ilan Ramon 2, Ness Ziona, Israel |
Web & social
| https://www.linkedin.com/company/18974367 |
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business models
B2B
Tags
biotechnologybiopharmaceuticalpharma-companiestherapeuticstreatmentsdegenerative-diseasesneurosciencedrug-discovery
Funding
| Total raised | — |
|---|---|
| Current stage | Seed |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}